Pharmaceuticals Global
Published · instant download
Global Oncology Market Strategic Research Report
By Type: Targeted Therapy (Small Molecules), Immunotherapy / Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), CAR-T & Advanced Cell Therapies, Conventional Chemotherapy, Hormone / Endocrine Therapy, Radiopharmaceuticals & Radiation Oncology
By Application: Lung Cancer (NSCLC & SCLC), Breast Cancer, Hematological Cancers (Blood/Lymphoma/MM), Colorectal Cancer, Prostate Cancer, Skin Cancer (Melanoma & NMSC), Gastric / Gastroesophageal Cancer, Ovarian, Cervical & Gynecologic Cancers, Bladder & Urologic Cancers, Other Solid Tumours & Rare Cancers
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: Merck &, Co Inc., Bristol-Myers Squibb, Roche Holding AG, AstraZeneca PLC, Johnson &, Johnson, Pfizer Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc.
Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2031
Length: 328 pages
Market size 2025
$278.6B
Billion USD
Forecast CAGR
11%
2025-2031
Forecast 2031
$521.1B
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America
Übersicht
The global oncology market is undergoing a historic structural transformation driven by three simultaneous pharmaceutical supercycles - the immunotherapy/checkpoint inhibitor expansion, the antibody-drug conjugate (ADC) commercial wave, and the scaling of CAR-T and advanced cell therapies - collectively representing one of the most significant pharmaceutical market growth stories of the decade.
The market is estimated at USD 278.6 billion in 2025 - the base year - anchored to real, publicly disclosed FY2025 revenues from ten leading oncology pharmaceutical companies, and is forecast to reach USD 521.0 billion by 2031, a compound annual growth rate of approximately 11.0% across the 2025–2031 forecast period.
Targeted Therapy remains the largest segment by value, Immunotherapy/Checkpoint Inhibitors close behind and the fastest-growing established segment, while Antibody-Drug Conjugates represent the fastest-growing therapy category overall. North America leads regionally, with Asia-Pacific the fastest-growing region through 2031.
Scope of Global Oncology Market Strategic Research Report
- This report covers the full spectrum of oncology therapeutics - pharmaceutical and biopharmaceutical products used in the treatment, prevention, and management of cancer - across all major global markets, with 2025 as the base year and forecasting to 2031.
- This report provides segment by type (Targeted Therapy (Small Molecules), Immunotherapy / Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), CAR-T & Advanced Cell Therapies, Conventional Chemotherapy, Hormone / Endocrine Therapy, Radiopharmaceuticals & Radiation Oncology) forecast data by value for the global oncology market.
- This report provides application segments (Lung Cancer (NSCLC & SCLC), Breast Cancer, Hematological Cancers (Blood/Lymphoma/MM), Colorectal Cancer, Prostate Cancer, Skin Cancer (Melanoma & NMSC), Gastric / Gastroesophageal Cancer, Ovarian, Cervical & Gynecologic Cancers, Bladder & Urologic Cancers, Other Solid Tumours & Rare Cancers) forecast data by value for the global oncology market.
- This report provides region-wise (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) forecast data by value for the global oncology market.
- This report also provides country-wise forecast data for the major markets across all five regions.
- This report identifies key growth drivers and inhibitors (pain points) affecting the global oncology market.
- This report provides company profiles including Company Overview, Key Products & Segments, Financial Performance, Business Strategy, and SWOT Analysis, along with competitive landscape for 328-page-detailed, verified companies in the global oncology market.
- This report provides Porter's Five Forces analysis for the global oncology market.
- This report provides PESTLE (Political, Economic, Social, Technological, Legal and Environmental) analysis for the global oncology market.
- This report provides SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis for the global oncology market.
- This report identifies key future trends in the global oncology market.
Segment by Type in Global Oncology Market Strategic Research Report
- Targeted Therapy (Small Molecules)
- Immunotherapy / Checkpoint Inhibitors
- Antibody-Drug Conjugates (ADCs)
- CAR-T & Advanced Cell Therapies
- Conventional Chemotherapy
- Hormone / Endocrine Therapy
- Radiopharmaceuticals & Radiation Oncology
Segment by Application in Global Oncology Market Strategic Research Report
- Lung Cancer (NSCLC & SCLC)
- Breast Cancer
- Hematological Cancers (Blood/Lymphoma/MM)
- Colorectal Cancer
- Prostate Cancer
- Skin Cancer (Melanoma & NMSC)
- Gastric / Gastroesophageal Cancer
- Ovarian, Cervical & Gynecologic Cancers
- Bladder & Urologic Cancers
- Other Solid Tumours & Rare Cancers
Segment by Region in Global Oncology Market Strategic Research Report
- North America
- USA
- Canada
- Rest of North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Switzerland
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Australia
- India
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Egypt
- South Africa
- Rest of MEA
Who can use the Global Oncology Market Strategic Research Report?
This research report is ideal for people who wish to gain a thorough understanding of the global oncology market. Some of the intended users for this report are:
- C-level executives and Company Directors in pharmaceutical, biotechnology, and oncology healthcare companies
- Industry consultants and Management consultants
- Marketing professionals and Business development professionals
- Investment managers, Financial professionals, and Venture Capitalists
- Bank Managers, M&A Managers, and Auditors
- Payers, Healthcare Policy Analysts, and Market Access professionals
- Portfolio Managers and Equity Research Analysts covering oncology and pharmaceuticals
- Anyone operating in the oncology drug value chain, from R&D through commercialization
Market snapshot
Global Oncology Market Strategic Research Report snapshot, 2025–2031
Source: Market Research Reports
Market size CAGR 11%
Regional growth momentum
Market share by segment
Key metrics
Base value
$278.6B
2025
Forecast
$521.1B
2031
CAGR
11%
2025–2031
Regionen
5
global
Key companies
Merck &Co Inc., Bristol-Myers Squibb, Roche Holding AG, AstraZeneca PLC, Johnson &Johnson, Pfizer Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc.
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
By Type
Targeted Therapy (Small Molecules)Immunotherapy / Checkpoint InhibitorsAntibody-Drug Conjugates (ADCs)CAR-T & Advanced Cell TherapiesConventional ChemotherapyHormone / Endocrine TherapyRadiopharmaceuticals & Radiation Oncology
By Application
Lung Cancer (NSCLC & SCLC)Breast CancerHematological Cancers (Blood/Lymphoma/MM)Colorectal CancerProstate CancerSkin Cancer (Melanoma & NMSC)Gastric / Gastroesophageal CancerOvarianCervical & Gynecologic CancersBladder & Urologic CancersOther Solid Tumours & Rare Cancers
Table of contents
Click a chapter to expand
01Executive Summary
- 1.1 Market Headline Metrics
- 1.2 Empirical Anchoring: Top-10 Company Revenue Base
- 1.3 The Three-Supercycle Growth Framework
- 1.3.1 Supercycle One: Immunotherapy Expansion and Combination Deepening
- 1.3.2 Supercycle Two: The ADC Commercial Wave
- 1.3.3 Supercycle Three: CAR-T and Advanced Cell Therapy Scaling
- 1.4 Segment Structure: Therapy Type and Market Positioning
- 1.5 Indication Landscape: Where Revenue Concentrates
- 1.6 Regional Structure and Growth Hierarchy
- 1.7 Strategic Implications and Report Objectives
02Industry Overview & Forecast
- 2.1 Global Oncology Market
- 2.2 The Three Supercycles Driving 11.0% CAGR
- 2.3 Overall Market Forecast 2025–2031
- 2.4 Methodology, Anchors, and Data Transparency
- 2.5 Segment Composition and Structural Shift
- 2.6 Cancer Indication Landscape
- 2.7 Regional Distribution and Growth Dynamics
- 2.8 Landmark Data Point: mRNA Neoantigen Cancer Vaccines
- 2.9 Summary Assessment
03Market Segmentation by Type
- 3.1 Overview of the Seven-Segment Framework
- 3.2 Targeted Therapy (Small Molecules)
- 3.3 Immunotherapy / Checkpoint Inhibitors
- 3.4 Antibody-Drug Conjugates (ADCs)
- 3.5 CAR-T and Advanced Cell Therapies
- 3.6 Conventional Chemotherapy
- 3.7 Hormone and Endocrine Therapy
- 3.8 Radiopharmaceuticals and Radiation Oncology
- 3.9 Cross-Segment Synthesis: Share Shift and Structural Implications
04Market Segmentation by Application
- 4.1 Overview of the Application Segmentation Framework
- 4.2 Lung Cancer (NSCLC and SCLC)
- 4.3 Breast Cancer
- 4.4 Hematological Cancers (Blood, Lymphoma, and Multiple Myeloma)
- 4.5 Colorectal Cancer
- 4.6 Prostate Cancer
- 4.7 Skin Cancer (Melanoma and Non-Melanoma Skin Cancer)
- 4.8 Gastric and Gastroesophageal Cancer
- 4.9 Ovarian, Cervical, and Gynecologic Cancers
- 4.10 Bladder and Urologic Cancers
- 4.11 Other Solid Tumours and Rare Cancers
- 4.12 Comparative Application Segment Growth Profile
- 4.13 Cross-Segment Analytical Observations
05Regional Market Forecast
- 5.1 North America
- 5.2 Europe
- 5.3 Asia-Pacific
- 5.4 Latin America
- 5.5 Middle East & Africa
06Country-Level Market Forecast
- 6.1 North America
- 6.1.1 USA
- 6.1.2 Canada
- 6.1.3 Rest N.America
- 6.2 Europe
- 6.2.1 Germany
- 6.2.2 France
- 6.2.3 UK
- 6.2.4 Italy
- 6.2.5 Spain
- 6.2.6 Switzerland
- 6.2.7 Rest Europe
- 6.3 Asia-Pacific
- 6.3.1 China
- 6.3.2 Japan
- 6.3.3 South Korea
- 6.3.4 Australia
- 6.3.5 India
- 6.3.6 Rest APAC
- 6.4 Latin America
- 6.4.1 Brazil
- 6.4.2 Mexico
- 6.4.3 Argentina
- 6.4.4 Colombia
- 6.4.5 Rest LatAm
- 6.5 Middle East & Africa
- Global Oncology Market Strategic Research Report 2026-2031
- 6.5.1 Saudi Arabia
- 6.5.2 UAE
- 6.5.3 Israel
- 6.5.4 Turkey
- 6.5.5 Egypt
- 6.5.6 South Africa
- 6.5.7 Rest MEA
07Growth Drivers & Inhibitors
- 7.1 Executive Summary of Force Dynamics
- 7.2 Growth Drivers
- 7.2.1 Pembrolizumab Label Expansion and the Broadening Checkpoint Inhibitor Paradigm
- 7.2.2 Antibody-Drug Conjugate Platform Acceleration
- 7.2.3 Targeted Therapy Volume Expansion into Adjuvant and Earlier Treatment Settings
- 7.2.4 CAR-T and Advanced Cell Therapy Commercial Scaling
- 7.2.5 Radiopharmaceutical Emergence as a Validated Commercial Platform
- 7.2.6 Asia-Pacific Market Expansion and Regulatory Modernisation
- 7.2.7 Demographic Tailwinds and Rising Global Cancer Incidence
- 7.3 Market Inhibitors
- 7.3.1 US Inflation Reduction Act Drug Price Negotiation
- 7.3.2 Biosimilar Penetration and Pricing Erosion in Maturing Segments
- 7.3.3 Manufacturing Complexity and CAR-T Access Constraints
- 7.3.4 European and Emerging Market Access and Reimbursement Barriers
- 7.3.5 Resistance Mechanisms and Durability Limitations in Targeted Therapy
- 7.3.6 Regulatory and Clinical Trial Execution Risk
- 7.4 Net Force Assessment
08Key Company Profiles
- 8.1 Merck & Co Inc.
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2025–2031)
- 8.2 Bristol-Myers Squibb
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2025–2031)
- 8.3 Roche Holding AG
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2025–2031)
- 8.4 AstraZeneca PLC
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2025–2031)
- 8.5 Johnson & Johnson
- Global Oncology Market Strategic Research Report 2026-2031
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2025–2031)
- 8.6 Pfizer Inc.
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2025–2031)
- 8.7 Novartis AG
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2025–2031)
- 8.8 AbbVie Inc.
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2025–2031)
- 8.9 Eli Lilly
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2025–2031)
- 8.10 Gilead Sciences
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2025–2031)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.1.1 Top 5 Players — Estimated Oncology Revenue Market Share (FY2025)
- 9.1.2 Structural Dynamics Underpinning Competitive Intensity
- 9.2 Competitive Intensity Assessment
- 9.2.1 Tier Structure and Revenue Stratification
- 9.2.2 Capacity vs. Demand Dynamics
- 9.2.3 Pricing Environment
- 9.2.4 Barriers to Entry and Exit
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 The Structural Architecture of Competition, 2025–2031
- 9.4.2 Emerging Competitive Threats
- 9.4.3 Consolidation vs. Fragmentation Outlook
- Global Oncology Market Strategic Research Report 2026-2031
- 9.4.4 Competitive Response Matrix
- 9.4.5 Strategic Recommendations for Market Participants, 2025–2031
- 9.4.6 Consolidation Outlook: 2025–2031
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.3.1 Key Factors
- 10.3.2 Market-Specific Context
- 10.3.3 Trend
- 10.3.4 Strategic Implication
- 10.4 Threat of Substitutes
- 10.4.1 Key Factors
- 10.4.2 Market-Specific Context
- 10.4.3 Trend
- 10.4.4 Strategic Implication
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Global Oncology Market — Strategic Macro-Environmental Assessment
- 11.2 Political
- 11.2.1 Government Oncology Prioritisation and National Cancer Strategies
- 11.2.2 Drug Pricing Legislation and Government Negotiation Authority
- 11.2.3 Geopolitical Fragmentation and Supply Chain Sovereignty
- 11.3 Economic
- 11.3.1 Macro-Financial Tailwinds Underpinning Market Expansion
- 11.3.2 Biopharmaceutical Financing Conditions and M&A Economics
- 11.3.3 Healthcare Budget Pressures and Access Economics
- 11.4 Social
- 11.4.1 Epidemiological Megatrend
- 11.4.2 Patient Empowerment, Advocacy, and Digital Health Literacy
- 11.4.3 Healthcare Workforce Constraints and Care Delivery Models
- 11.5 Technological
- 11.5.1 The ADC Technology Revolution
- 11.5.2 Artificial Intelligence and Multi-Omics in Drug Discovery
- 11.5.3 CAR-T Manufacturing Technology and Allogeneic Platforms
- 11.5.4 Biomarker Stratification and Companion Diagnostics
- 11.5.5 Radiopharmaceutical Technology Development
- 11.6 Legal
- 11.6.1 Intellectual Property Frameworks and Patent Cliff Dynamics
- 11.6.2 Regulatory Approval Frameworks
- 11.6.3 Clinical Trial Legal Frameworks and International Harmonisation
- 11.6.4 Liability, Pharmacovigilance, and Post-Market Safety Law
- 11.7 Environmental
- 11.7.1 Sustainability, ESG Commitments, and Pharmaceutical Manufacturing
- 11.7.2 Climate Change as a Health Burden Amplifier
- 11.7.3 Pharmaceutical Waste and Environmental Contamination
- 11.8 PESTLE Summary Assessment
12SWOT Analysis
- 12.1 Global Oncology Market Strategic Assessment
- 12.2 Overview and Methodology
- 12.3 Strengths
- 12.3.1 Unprecedented Commercial Scale and Revenue Momentum
- 12.3.2 Dominant Blockbuster Platform Anchors
- 12.3.3 Three Simultaneous Innovation Supercycles
- Global Oncology Market Strategic Research Report 2026-2031
- 12.3.4 Geographic Diversification and Emerging Market Optionality
- 12.3.5 Radiopharmaceuticals as a Validated Emerging Platform
- 12.4 Weaknesses
- 12.4.1 Manufacturing Complexity and Scalability Constraints
- 12.4.2 High Concentration Risk in a Small Number of Blockbusters
- 12.4.3 Affordability, Reimbursement, and Pricing Sustainability
- 12.4.4 Clinical and Regulatory Attrition in Late-Stage Pipelines
- 12.5 Opportunities
- 12.5.1 Indication Expansion and First-Line Migration of Established Products
- 12.5.2 Allogeneic CAR-T: From Niche to Mainstream
- 12.5.3 Asia-Pacific Market Development and NMPA Acceleration
- 12.5.4 Radiopharmaceutical Pipeline Expansion
- 12.5.5 Biomarker-Driven Precision Medicine and Companion Diagnostics
- 12.5.6 Combination Regimen Innovation
- 12.6 Threats
- 12.6.1 Keytruda Patent Cliff and Biosimilar Entry Risk
- 12.6.2 Drug Pricing Regulation and Government Reimbursement Intervention
- 12.6.3 Competitive Intensity and Therapy Category Disruption
- 12.6.4 China-US Geopolitical and Supply Chain Risk
- 12.6.5 Clinical Pipeline Failure and Late-Stage Trial Risk
- 12.6.6 Macroeconomic Pressures and Healthcare Budget Constraints
- 12.7 Strategic Synthesis
13Future Trends & Outlook
- 13.1 Executive Outlook Summary
- 13.2 Therapeutic Modality Trajectories
- 13.2.1 Immunotherapy: From Expansion to Optimisation
- 13.2.2 Antibody-Drug Conjugates: The Highest-Conviction Growth Segment
- 13.2.3 CAR-T and Advanced Cell Therapies: Scaling Toward Mainstream
- 13.2.4 Radiopharmaceuticals: Platform Validation and Pipeline Depth
- 13.3 Pipeline Productivity and Regulatory Environment
- 13.3.1 NDA/BLA Filing Volume and Regulatory Throughput
- 13.3.2 Biomarker-Driven Label Expansion
- 13.4 Combination Regimen Convergence
- 13.4.1 The IO + ADC Combination Paradigm
- 13.4.2 Targeted Therapy + IO and Bispecific Antibody Platforms
- 13.5 Manufacturing, Access, and Economics
- 13.5.1 Cost-of-Goods Trajectory and Margin Implications
- 13.5.2 Pricing, Reimbursement, and Access Dynamics
- 13.6 Geographic Market Development
- 13.6.1 Asia-Pacific: The Decisive Growth Geography
- 13.6.2 North America: Continued Dominance with Structural Adjustment
- 13.6.3 Europe: Value-Based Framework Adaptation
- 13.7 Competitive Landscape Dynamics
- 13.7.1 Consolidation and Pipeline Acquisition
- 13.7.2 Biosimilar and Generic Competitive Pressure
- 13.8 Disruptive Risk Factors and Scenario A
Tables and figures
List of Exhibits
- Exhibit 3.1 Global Oncology Market — Overall Forecast 2026–2031 (USD Billion)
- Exhibit 3.2 Key Forecast Dynamics — Global Oncology Market 2025–2031
- Exhibit 3.3 Market Segment Share by Therapy Type — Global Oncology Forecast 2025 (IN %)
- Exhibit 3.4 Market Segment Share by Therapy Type — Global Oncology Forecast 2031 (IN %)
- Exhibit 3.5 Targeted Therapy (Small Molecules) Market Forecast 2025-2031in USD Billion
- Exhibit 3.6 Immunotherapy / Checkpoint Inhibitors Market Forecast 2025-2031in USD Billion
- Exhibit 3.7 Antibody-Drug Conjugates (ADCs) Market Forecast 2025-2031in USD Billion
- Exhibit 3.8 CAR-T & Advanced Cell Therapies Market Forecast 2025-2031in USD Billion
- Exhibit 3.9 Conventional Chemotherapy Market Forecast 2025-2031in USD Billion
- Exhibit 3.10 Hormone / Endocrine Therapy Market Forecast 2025-2031in USD Billion
- Exhibit 3.11 Radiopharmaceuticals & Radiation Market Forecast 2025-2031in USD Billion
- Exhibit 3.12 YoY ONCOLOGY MARKET CAGR GROWTH BY SEGMENT (%) - 2026-31
- Exhibit 3.13 Segment-Level Forecast — by Cancer Indication
- Exhibit 3.14 Global Oncology Market Application by Market Share in % in 2025
- Exhibit 3.15 Global Oncology Market Application by Market Share in % in 2031
- Exhibit 3.16 Lung Cancer (NSCLC & SCLC) Market Forecast 2025-2031 in USD Billion
- Exhibit 3.17 Breast Cancer Market Forecast Market Forecast 2025-2031 in USD Billion
- Exhibit 3.18 Hematological Cancers (Blood/Lymphoma/MM) Market Forecast 2025-2031 in USD Billion
- Exhibit 3.19 Colorectal Cancer Market Forecast 2025-2031 in USD Billion
- Exhibit 3.20 Prostate Cancer Market Forecast 2025-2031 in USD Billion
- Exhibit 3.21 Skin Cancer (Melanoma & NMSC) Market Forecast 2025-2031 in USD Billion
- Exhibit 3.22 Gastric / Gastroesophageal Cancer Market Forecast 2025-2031 in USD billion
- Exhibit 3.23 Ovarian, Cervical & Gynecologic Market Forecast 2025-2031 in USD billion
- Exhibit 3.24 Bladder & Urologic Cancers Market Forecast 2025-2031 in USD Billion
- Exhibit 3.25 Other Solid Tumours & Rare Cancers Market Forecast 2025-2031in USD Billion
- Exhibit 3.26 Region wise Oncology Market Share 2025 in %
- Exhibit 3.27 Region wise Oncology Market Share 2031 in %
- Exhibit 3.28 Region wise Oncology Market CAGR Growth 2025-2031 in %
- Exhibit 3.29 North America Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.30 Europe Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.31 APAC Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.32 Latin America Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.33 Middle East & Africa Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.34 USA Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.35 Canada Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.36 Rest of America Canada Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.37 China Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.38 Japan Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.39 India Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.40 South Korea Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.41 Australia Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.42 Rest of APAC Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.43 Germany Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.44 France Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.45 UK Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.46 Italy Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.47 Spain Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.48 Switzerland Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.49 Rest of Europe Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.50 Brazil Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.51 Mexico Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.52 Argentina Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.53 Colombia Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.54 Rest of Latin America Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.55 Saudi Arabia Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.56 UAE Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.57 Israel Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.58 Turkey Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.59 Egypt Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.60 South Africa Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 3.61 Rest of MEA Oncology Market Forecast 2025-2031 in USD Billion
- Exhibit 6.1 Porter’s Five Forces Analysis of Global Oncology Market
- Exhibit 7.1 Key Players in Global Oncology Market – Competitive Landscape
- Exhibit 7.2 SWOT Analysis — Merck & Co Inc.
- Exhibit 7.3 SWOT Analysis — Bristol-Myers Squibb.
- Exhibit 7.4 SWOT Analysis — AstraZeneca PLC
- Exhibit 7.5 SWOT Analysis — Roche Holding AG
- Exhibit 7.6 SWOT Analysis — Johnson & Johnson Source
- Exhibit 7.7 SWOT Analysis — Pfizer Inc.
- Exhibit 7.8 SWOT Analysis — Novartis AG
- Exhibit 7.9 SWOT Analysis — AbbVie Inc.
- Exhibit 7.10 SWOT Analysis — Eli Lilly and Company
- Exhibit 7.11 SWOT Analysis — Gilead Sciences Inc.
- Exhibit 9.1 SWOT Analysis of Global Oncology Market
Frequently asked questions
What is the size of the global oncology market?
The market is estimated at USD 278.6 billion in 2025, projected to reach USD 521.0 billion by 2031, growing at a CAGR of approximately 11.0% across the forecast period.
Which therapy segment is the largest in the oncology market?
Targeted Therapy (Small Molecules) is the largest segment by value, anchored by CDK4/6, EGFR/ALK, and BTK inhibitors. Immunotherapy/Checkpoint Inhibitors is close behind and the fastest-growing established segment, anchored by Keytruda and Opdivo.
Which therapy segment is growing fastest?
Antibody-Drug Conjugates (ADCs) are the fastest-growing therapy segment overall, led by products such as Enhertu.
Which companies are profiled in this report?
Ten companies: Merck & Co, Bristol-Myers Squibb, Roche, AstraZeneca, Johnson & Johnson, Pfizer, Novartis, AbbVie, Eli Lilly, and Gilead Sciences.
Which region leads the global oncology market?
North America leads, driven by the United States. Asia-Pacific is the fastest-growing region, driven by expanding regulatory modernisation and rising cancer incidence across the region.
What forecast period does this report cover?
The report covers a forecast horizon of 2025–2031, with 2025 as the base year.
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
01
Secondary Research & Data Aggregation
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
02
Market Sizing — Bottom-Up & Top-Down
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
03
Competitive Intelligence
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
04
Demand Forecasting
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
05
Analyst Validation & Quality Assurance
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
06
Continuous Updates
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Related reports
Navadhi Market Research · PharmaceuticalsGlobal Peptide Market Strategic Intelligence Suite
The Global Peptide Market Strategic Intelligence Suite 2026–2031 is Navadhi Market Research's most comprehensive intelligence offering on the global peptide industry…
▲ 14.74%CAGR2024–2032
11.000,00 $ from
Forecast $252.9B by 2032
Navadhi Market Research · PharmaceuticalsGlobal Peptide Therapy Market Strategic Research Report
The global peptide therapy market is undergoing an unprecedented structural transformation driven by the GLP-1 revolution - the extraordinary commercial success of G…
▲ 14.74%CAGR2025–2031
3.500,00 $ from
Forecast $192.1B by 2031
Navadhi Market Research · PharmaceuticalsGlobal Cosmetic Peptides Market Strategic Research Report
The global cosmetic peptides market is positioned for sustained double-digit growth through 2031. Anti-aging remains the dominant application, but emerging opportuni…
▲ 13.84%CAGR2025–2031
3.500,00 $ from
Forecast $2.1B by 2031
Select a license
from 3.500,00 $
Optional add-ons
Published · instant download
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →
Talk to a research advisor
USA: +1-302-703-9904
India: +91-8762746600
Free sample
Request a free sample
Receive a sample of Global Oncology Market Strategic Research Report before you buy.
Custom Research
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Wire Transfer
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Trusted by
Leading Brands in This Industry
